Clinical trials: Intermediate Age-Related Macular Degeneration
Age Related Macular Degeneration
Usability of the Foresee Home in Intermediate Age Related Macular Degeneration (AMD) Patients
The study purpose is to demonstrate that the target population can receive a packed FORESEE HOME unpack it, install and operate it to an extent that the FORESEE HOME can monitor them for changes in the visual field with good…
- Trial name
- UU2 (NCT00748384)
- Where
- 2 sites in Israel
- Volunteers
- 30 people
- Sponsor
- Notal Vision Ltd.
Age-Related Macular Degeneration
Intermediate Age-related Macular Degeneration - Multimodal Analysis and Longitudinal Study
Study: observational prospective clinical study. Study population: Subjects over 55 years old with drusen secondary to intermediate AMD. Recruitment: at the Medical Retinal Consultation from the Ophthalmology Department of CHULC.
- Trial name
- Imaging4iAMD (NCT06355830)
- Testing
- Orthoptic assessment (Outcome measure)
- Where
- Portugal
- Volunteers
- 150 people
- Sponsor
- Universidade Nova de Lisboa
Macular Degeneration, Senile, Laser Burn of Retina
Subthreshold Laser Treatment for Reticular Pseudodrusen Secondary to Age-related Macular Degeneration
Prospective, randomized, controlled, longitudinal, interventional multicentric study involving patients with reticular pseudodrusen secondary to AMD.
- Conditions
- Macular Degeneration, Senile, Laser Burn of Retina, Macular Degeneration Intermediate, Macular Degeneration, Dry
- Trial name
- PASCAL-RPD (NCT04847635)
- Testing
- Pascal Synthesis 577 sub-threshold laser (Topcon Corporation, Tokyo, Japan)
- Where
- 3 sites in Italy
- Volunteers
- 50 people
- Sponsor
- Ospedale San Raffaele
Age Related Macular Degeneration
Safety of 16.5 mg (3.3%) CGC-11047 Once Every 2 Weeks vs. Once Every 4 Weeks in Patients With CNV Due to AMD
The purpose of this research study is to determine how safe and effective subconjunctival injections of CGC-11047 are in subjects with wet age related macular degeneration at two different dosing intervals.
- Trial name
- NCT00446654
- Testing
- CGC-11047
- Where
- 8 sites in United States, Mexico and 1 more
- Volunteers
- 43 people
- Sponsor
- Progen Pharmaceuticals